SCHEMBL278932

SCHEMBL278932

CC(C)(C)OC(=O)N1C(=O)C(=Cc2cccc(Cl)c2F)c2ccc(Cl)cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.35
CNR1 P21554 2/20 0.34
CNR2 P34972 1/20 0.34
CYP3A4 P08684 3/20 0.33
CYP3A5 P20815 2/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 4/20 0.33
KMT2A Q03164 3/20 0.33
HPGD P15428 3/20 0.33
TDP1 Q9NUW8 3/20 0.33
LMNA P02545 1/20 0.33
APEX1 P27695 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
BCHE P06276 1/20 0.33
STS P08842 1/20 0.32
APP P05067 1/20 0.32
SNCA P37840 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL275576 0.92 CYP3A4 (0.35) FAAHCNR1CNR2CYP3A4CYP3A5
SCHEMBL275240 0.89 CNR1 (0.33) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL275241 0.89 CNR1 (0.33) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL275083 0.87 CYP3A4 (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL275084 0.87 CYP3A4 (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL279502 0.87 CYP3A4 (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL13929332 0.86 CNR1 (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL279181 0.85 AMY1A (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL275035 0.85 AMY1A (0.37) CNR1CNR2CYP3A4CYP3A5MAPT
SCHEMBL275036 0.85 AMY1A (0.37) CNR1CNR2CYP3A4CYP3A5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT FAAH 4838/4885CNR1 3227/4885CNR2 4264/4885
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES RB1, PKD1, KRAS FAAH 4833/4885CNR1 1644/4885CNR2 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.